Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 249

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

Open access
Verma, Sunil, Bartlett, Cynthia Huang, Schnell, Patrick, DeMichele, Angela M., Loi, Sherene, Ro, Jungsil, Colleoni, Marco, Iwata, Hiroji, Harbeck, Nadia, Cristofanilli, Massimo, Zhang, Ke, Thiele, Alexandra, Turner, Nicholas C., Rugo, Hope S. · 2016 · The Oncologist

Abstract

Background.: Palbociclib enhances endocrine therapy and improves clinical outcomes in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Because this is a new target, it is clinically important to understand palbociclib’s safety profile to effectively manage toxicity and optimize clinical benefit. Materials and Methods.: Patients with endocrine-resistant, HR-positive/HER2-negative MBC (n = 521) were randomly assigned 2:1 to receive fulvestrant (500 mg intramuscular injection) with or without goserelin with oral palbociclib (125 mg daily; 3 weeks on/1 week off) or placebo. Safety assessments at baseline and day 1 of each cycle included blood counts on day 15 for the first 2 cycles. Hematologic toxicity was assessed by using laboratory data. Results.: A total of 517 patients were treated (palbociclib, n = 345; placebo, n = 172); median follow-up was 8.9 months. With palbociclib, neutropenia was the most common grade 3 (55%) and 4 (10%) adverse event; median times to onset and duration of grade ≥3 episodes were 16 and 7 days, respectively. Asian ethnicity and below-median neutrophil counts at baseline were significantly associated with an increased chance of developing grade 3–4 neutropenia with palbociclib. Dose modifications for grade 3–4 neutropenia had no adverse effect on progression-free survival. In the palbociclib arm, febrile neutropenia occurred in 3 (<1%) patients. The percentage of grade 1–2 infections was higher than in the placebo arm. Grade 1 stomatitis occurred in 8% of patients. Conclusion.: Palbociclib plus fulvestrant treatment was well-tolerated, and the primary toxicity of asymptomatic neutropenia was effectively managed by dose modification without apparent loss of efficacy. This study appears at ClinicalTrials.gov, NCT01942135.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2016-0097

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 14

  1. Hayes, 2015, Mechanisms of endocrine resistance in breast cancer: An overview of the proposed roles of noncoding RNA, Breast Cancer Res, 17, 40, 10.1186/s13058-015-0542-y · DOI · Paper page
  2. Cristofanilli, 2016, Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial, Lancet Oncol, 17, 425, 10.1016/S1470-2045(15)00613-0 · DOI · Paper page
  3. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 2009
  4. Beaver, 2012, The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer, Future Oncol, 8, 651, 10.2217/fon.12.49 · DOI
  5. Baselga, 2015, PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial
  6. Harbeck, 2015, Double-blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2−ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes, Eur J Cancer, 51, S270, 10.1016/S0959-8049(16)30767-5 · doi:10.1016/s0959-8049(16)30767-5
  7. Hu, 2016, Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies, Clin Cancer Res, 22, 2000, 10.1158/1078-0432.CCR-15-1421 · DOI · Paper page
  8. Tofts, 2011, Doubts concerning the recently reported human neutrophil lifespan of 5.4 days, Blood, 117, 6050, 10.1182/blood-2010-10-310532 · DOI
  9. Crawford, 2004, Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management, Cancer, 100, 228, 10.1002/cncr.11882 · DOI · Paper page
  10. Lyman, 2006, Chemotherapy dose intensity and quality cancer care, Oncology (Williston Park), 20, 16
  11. Roberts, 2012, Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy, J Natl Cancer Inst, 104, 476, 10.1093/jnci/djs002 · DOI · Paper page
  12. Bhatt, 2004, Review: Drug-induced neutropenia–pathophysiology, clinical features, and management, Ann Clin Lab Sci, 34, 131
  13. Lalami, 2006, Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis, Ann Oncol, 17, 507, 10.1093/annonc/mdj092 · DOI
  14. ClinicalTrials.gov. Study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer. 2016

Cited by

See all 249

Metadata

Authors
Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., Colleoni, M., Iwata, H., Harbeck, N., Cristofanilli, M., Zhang, K., Thiele, A., Turner, N. C., & Rugo, H. S.
Venue
The Oncologist
Published
2016-07-01
Volume
21
Issue
10
Pages
1165-1175
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2474699717
Cited by
249
References
6
FWCI
23.83
Type
journal article
Language
en
Open access
green
Funders
  • Pfizer Inc.
  • AstraZeneca
  • Susan Reinwald, of Complete Healthcare Communications, LLC

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.